552 related articles for article (PubMed ID: 28365644)
1. High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial.
Massard C; Michiels S; Ferté C; Le Deley MC; Lacroix L; Hollebecque A; Verlingue L; Ileana E; Rosellini S; Ammari S; Ngo-Camus M; Bahleda R; Gazzah A; Varga A; Postel-Vinay S; Loriot Y; Even C; Breuskin I; Auger N; Job B; De Baere T; Deschamps F; Vielh P; Scoazec JY; Lazar V; Richon C; Ribrag V; Deutsch E; Angevin E; Vassal G; Eggermont A; André F; Soria JC
Cancer Discov; 2017 Jun; 7(6):586-595. PubMed ID: 28365644
[TBL] [Abstract][Full Text] [Related]
2. Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial.
Bertucci F; Gonçalves A; Guille A; Adelaïde J; Garnier S; Carbuccia N; Billon E; Finetti P; Sfumato P; Monneur A; Pécheux C; Khran M; Brunelle S; Mescam L; Thomassin-Piana J; Poizat F; Charafe-Jauffret E; Turrini O; Lambaudie E; Provansal M; Extra JM; Madroszyk A; Gilabert M; Sabatier R; Vicier C; Mamessier E; Chabannon C; Pakradouni J; Viens P; André F; Gravis G; Popovici C; Birnbaum D; Chaffanet M
Genome Med; 2021 May; 13(1):87. PubMed ID: 34006291
[TBL] [Abstract][Full Text] [Related]
3. Molecular Screening for Cancer Treatment Optimization (MOSCATO-01) in Pediatric Patients: A Single-Institutional Prospective Molecular Stratification Trial.
Harttrampf AC; Lacroix L; Deloger M; Deschamps F; Puget S; Auger N; Vielh P; Varlet P; Balogh Z; Abbou S; Allorant A; Valteau-Couanet D; Sarnacki S; Gamiche-Rolland L; Meurice G; Minard-Colin V; Grill J; Brugieres L; Dufour C; Gaspar N; Michiels S; Vassal G; Soria JC; Geoerger B
Clin Cancer Res; 2017 Oct; 23(20):6101-6112. PubMed ID: 28733441
[No Abstract] [Full Text] [Related]
4. Molecular profiling of advanced solid tumours. The impact of experimental molecular-matched therapies on cancer patient outcomes in early-phase trials: the MAST study.
Gambardella V; Lombardi P; Carbonell-Asins JA; Tarazona N; Cejalvo JM; González-Barrallo I; Martín-Arana J; Tébar-Martínez R; Viala A; Bruixola G; Hernando C; Blasco I; Papaccio F; Martínez-Ciarpaglini C; Alfaro-Cervelló C; Seda-García E; Blesa S; Chirivella I; Castillo J; Montón-Bueno JV; Roselló S; Huerta M; Pérez-Fidalgo A; Martín-Martorell P; Insa-Mollá A; Fleitas T; Rentero-Garrido P; Zúñiga-Trejos S; Cervantes A; Roda D
Br J Cancer; 2021 Oct; 125(9):1261-1269. PubMed ID: 34493820
[TBL] [Abstract][Full Text] [Related]
5. Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience.
Schwaederle M; Parker BA; Schwab RB; Daniels GA; Piccioni DE; Kesari S; Helsten TL; Bazhenova LA; Romero J; Fanta PT; Lippman SM; Kurzrock R
Mol Cancer Ther; 2016 Apr; 15(4):743-52. PubMed ID: 26873727
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive tumor profiling-guided therapy in rare or refractory solid cancer: A feasibility study in daily clinical practice.
Ibrahim T; Ahmadie A; Rassy E; Karak FE; Hanna C; Farhat F; Kattan J; Ghosn M
Bull Cancer; 2020 Apr; 107(4):410-416. PubMed ID: 32145962
[TBL] [Abstract][Full Text] [Related]
7. Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial.
Verlingue L; Malka D; Allorant A; Massard C; Ferté C; Lacroix L; Rouleau E; Auger N; Ngo M; Nicotra C; De Baere T; Tselikas L; Ba B; Michiels S; Scoazec JY; Boige V; Ducreux M; Soria JC; Hollebecque A
Eur J Cancer; 2017 Dec; 87():122-130. PubMed ID: 29145038
[TBL] [Abstract][Full Text] [Related]
8. Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers.
Radovich M; Kiel PJ; Nance SM; Niland EE; Parsley ME; Ferguson ME; Jiang G; Ammakkanavar NR; Einhorn LH; Cheng L; Nassiri M; Davidson DD; Rushing DA; Loehrer PJ; Pili R; Hanna N; Callaghan JT; Skaar TC; Helft PR; Shahda S; O'Neil BH; Schneider BP
Oncotarget; 2016 Aug; 7(35):56491-56500. PubMed ID: 27447854
[TBL] [Abstract][Full Text] [Related]
9. Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study.
Wheler JJ; Janku F; Naing A; Li Y; Stephen B; Zinner R; Subbiah V; Fu S; Karp D; Falchook GS; Tsimberidou AM; Piha-Paul S; Anderson R; Ke D; Miller V; Yelensky R; Lee JJ; Hong DS; Kurzrock R
Cancer Res; 2016 Jul; 76(13):3690-701. PubMed ID: 27197177
[TBL] [Abstract][Full Text] [Related]
10. Community-driven development of a modified progression-free survival ratio for precision oncology.
Mock A; Heilig CE; Kreutzfeldt S; Huebschmann D; Heining C; Schröck E; Brors B; Stenzinger A; Jäger D; Schlenk R; Glimm H; Fröhling S; Horak P;
ESMO Open; 2019; 4(6):e000583. PubMed ID: 31798980
[TBL] [Abstract][Full Text] [Related]
11. Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial.
Stockley TL; Oza AM; Berman HK; Leighl NB; Knox JJ; Shepherd FA; Chen EX; Krzyzanowska MK; Dhani N; Joshua AM; Tsao MS; Serra S; Clarke B; Roehrl MH; Zhang T; Sukhai MA; Califaretti N; Trinkaus M; Shaw P; van der Kwast T; Wang L; Virtanen C; Kim RH; Razak AR; Hansen AR; Yu C; Pugh TJ; Kamel-Reid S; Siu LL; Bedard PL
Genome Med; 2016 Oct; 8(1):109. PubMed ID: 27782854
[TBL] [Abstract][Full Text] [Related]
12. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
[TBL] [Abstract][Full Text] [Related]
13. Copenhagen Prospective Personalized Oncology (CoPPO)-Clinical Utility of Using Molecular Profiling to Select Patients to Phase I Trials.
Tuxen IV; Rohrberg KS; Oestrup O; Ahlborn LB; Schmidt AY; Spanggaard I; Hasselby JP; Santoni-Rugiu E; Yde CW; Mau-Sørensen M; Nielsen FC; Lassen U
Clin Cancer Res; 2019 Feb; 25(4):1239-1247. PubMed ID: 30274980
[TBL] [Abstract][Full Text] [Related]
14. Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to delivery.
Bryce AH; Egan JB; Borad MJ; Stewart AK; Nowakowski GS; Chanan-Khan A; Patnaik MM; Ansell SM; Banck MS; Robinson SI; Mansfield AS; Klee EW; Oliver GR; McCormick JB; Huneke NE; Tagtow CM; Jenkins RB; Rumilla KM; Kerr SE; Kocher JA; Beck SA; Fernandez-Zapico ME; Farrugia G; Lazaridis KN; McWilliams RR
Oncotarget; 2017 Apr; 8(16):27145-27154. PubMed ID: 28423702
[TBL] [Abstract][Full Text] [Related]
15. Molecular analysis for refractory rare cancers: Sequencing battle continues - learnings for the MOSCATO-01 study.
Debien V; Vignot S; Massard C; Malouf G; Hollebecque A; Scoazec JY; Michiels S; Verlingue L
Crit Rev Oncol Hematol; 2023 Jan; 181():103888. PubMed ID: 36460264
[TBL] [Abstract][Full Text] [Related]
16. Next-generation sequencing in patients with advanced cancer: are we ready for widespread clinical use? A single institute's experience.
Grenader T; Tauber R; Shavit L
Anticancer Drugs; 2016 Oct; 27(9):899-907. PubMed ID: 27384593
[TBL] [Abstract][Full Text] [Related]
17. Use of comprehensive genomic profiling to direct point-of-care management of patients with gynecologic cancers.
Rodriguez-Rodriguez L; Hirshfield KM; Rojas V; DiPaola RS; Gibbon D; Hellmann M; Isani S; Leiser A; Riedlinger GM; Wagreich A; Ali SM; Elvin JA; Miller VA; Ganesan S
Gynecol Oncol; 2016 Apr; 141(1):2-9. PubMed ID: 27016222
[TBL] [Abstract][Full Text] [Related]
18. Next-generation Sequencing-based genomic profiling: Fostering innovation in cancer care?
Fernandes GS; Marques DF; Girardi DM; Braghiroli MIF; Coudry RA; Meireles SI; Katz A; Hoff PM
Clinics (Sao Paulo); 2017 Oct; 72(10):588-594. PubMed ID: 29160420
[TBL] [Abstract][Full Text] [Related]
19. Clinical Trial Accrual Targeting Genomic Alterations After Next-Generation Sequencing at a Non-National Cancer Institute-Designated Cancer Program.
Mantripragada KC; Olszewski AJ; Schumacher A; Perez K; Birnbaum A; Reagan JL; Mega A; Khurshid H; Bartley C; Lombardo A; Rossiter R; Papa A; Bakalarski P; Safran H
J Oncol Pract; 2016 Apr; 12(4):e396-404. PubMed ID: 26907448
[TBL] [Abstract][Full Text] [Related]
20. The NEXT-1 (Next generation pErsonalized tX with mulTi-omics and preclinical model) trial: prospective molecular screening trial of metastatic solid cancer patients, a feasibility analysis.
Kim ST; Lee J; Hong M; Park K; Park JO; Ahn T; Park SH; Park YS; Lim HY; Sun JM; Ahn JS; Ahn MJ; Kim HC; Sohn TS; Choi DI; Cho JH; Heo JS; Kwon W; Uhm SW; Lee H; Min BH; Hong SN; Kim DH; Jung SH; Park W; Kim KM; Kang WK; Park K
Oncotarget; 2015 Oct; 6(32):33358-68. PubMed ID: 26396172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
